The Cell Fusion Kit(HVJ-E) (MSV1002) has now been delivered to customers in multiple countries and regions，we sincerely thank our customers for their trust and support of our products. We will promptly optimize our products based on customer feedback to ensure that every customer successfully completes their experiments.

This study developed a temperature-sensitive and less immunogenic Sendai virus (ts SeV) for CRISPR-Cas9 delivery, achieving over 90% CCR5 editing in human CD34+ HSPCs and CD14+ monocytes, significantly inhibiting HIV-1 infection. The ts SeV offers a safe, efficient, and versatile platform for gene editing and personalized medicine.

This study develops an optimized plasmid transfection protocol for primary human cardiac fibroblasts, aiming to improve gene transfer efficiency and minimize toxicity. Despite an efficiency below 5%, the protocol supports experiments like luciferase assays and allows profiling of fibroblast and cardiac fibroblast markers (VIM, TCF21). The findings provide a valuable tool for advancing cardiovascular research.

This study develops lipid-polymer hybrid nanocarriers (FLNPs) to enhance gene delivery for ischemic diseases. FLNPs improve gene transfection, avoid lysosomes, and target the nucleus. Loaded with Hepatocyte Growth Factor (pHGF) and Catalase (pCAT) plasmids, FLNPs boosted cell resistance to oxidative stress and improved recovery in a mouse ischemia model, without causing metabolic disturbances. FLNPs show promise for effective gene therapy in ischemia.

This study created four healthy cynomolgus monkeys using pronuclear transfer, with minimal mtDNA carryover and stable mtDNA dynamics. It highlights the potential of this method for preventing mtDNA diseases and advancing mitochondrial replacement therapies in humans.T（The subsequent HVJ-E cell fusion reagent product procurement from the Chinese Academy of Sciences(Shanghai) has been replaced with Melton's.)

The passage introduces intestine-specific gene transfer (iGT), a method for delivering small molecules like siRNAs and plasmids into the intestinal epithelium of living mice using the Hemagglutinating Virus of Japan Envelope (HVJ-E). This technique offers a faster and more efficient alternative to traditional genetic engineering in mice, aiding research on intestinal stem cell-driven tissue renewal and tumorigenesis.

"Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)" is a preliminary study showing that oncolytic Sendai virus (SeV) can inhibit tumor growth in canine mast cell tumors (MCT) by selectively targeting and destroying tumor cells. This research provides early evidence for SeV as a potential cancer therapy and supports future clinical trials.

This phase I study evaluated HVJ-E, an inactivated Sendai virus particle, for safety and preliminary efficacy in chemotherapy-resistant MPM. High doses led to stable disease, while low doses saw progression, indicating a dose-dependent antitumor effect with no serious adverse events. Findings support a phase II trial with higher doses. Trial registration: UMIN000019345.

The article discusses the research on the use of Sendai virus (SeV) for treating congenital and chemotherapy-induced infertility. The study shows that SeV successfully restores fertility in mice by enhancing KITL expression without the risk of viral gene integration. SeV therapy demonstrates potential for protecting fertility and offers new insights for future clinical applications.

This article describes how one of our customers who applied MeltonVEC-Sendai iPSC Reprogramming Kit on the transduction of newborn fibroblasts into iPSCs successfully. There are detailed materials and methodology, highly illustrated results in this informative article.

Melton provides customized packaging F-defective Sendai virus service for CTSCB of the University of Hong Kong.